Advertising claims made by RDK Global for the company’s Provailen dietary supplement have been referred to the Federal Trade Commission. The National Advertising Division alerted the FTC to these claims after the company failed to provide a substantive response to its inquiries about the company’s advertising content.
  
The advertising claims at issue were challenged by the Council for Responsible Nutrition (CRN) as part of an initiative to expand NAD’s review of claims made for dietary supplements. CRN challenged certain performance and establishment claims that include:

• “Stops Arthritis Pain At The Source!”
• “Relieves Arthritis Inflammation!”
• “Zero Side Effects!”
• “Manufactured in F.D.A. Approved Facility!”
• “No Medication Interactions!”
• “87.6% of clients asked experience up to 90% reduction in arthritis pain.”
• “Provailen uses Reishi mushroom as part of its 3-in-1 formula to rebalance your immune system and relieve your inflammation.” 
• “…I ordered Provailen and started taking 3 times a day.  After taking Provailen for 2.5 months I started to notice that most of my joint pain was gone but my shoulder pain was still there.  But I still continued taking Provailen.  This time I was taking twice a day.  After taking Provailen for 4 months my shoulder pain started to subside.  That was the most amazing thing to me.  Now 90% of the pain is gone.  Thank God I did not go for the surgery.  Now I am taking Provailenonce a day.  Thanks to Provailen that has helped me a lot.”

CRN argued that the challenged claims suggest that Provailen may be used to treat pain and manage serious medical conditions and reasonably convey the message that the supplement is an alternative to Food and Drug Administration-approved medication, which CRN maintained may encourage consumers to forego conventional medical treatment. CRN further argued that the expressed and implied benefits claims in the testimonials must reflect “typical results” that consumers can expect to achieve when consuming the product as directed. 
 
The advertiser failed to file a substantive written reply in response to NAD’s inquiry or provide any evidence to substantiate the challenged claims and testimonials. Based on the advertiser’s failure to file a substantive written response, NAD is referring this matter to the Federal Trade Commission pursuant to section 2.10 (A) of the NAD/NARB Procedures.